Not so good deal, page-21

Myownmoney - you and lockstock are getting to the key points about the selection of ITF.

In the US, pharma companies have field sales reps who visit doctors (and maybe pharmacists) in their offices and present the reasons to prescribe their company's drugs. Larger companies, more reps, more credibility. Hiring 60 new reps barely moves the ball. It could take years to train new reps, acquaint them with their sales territories, and have them build credibility with doctors.

TV and magazine ads for prescription drugs have become significant in the US. So there is some hope for visibility here, but that would take a big ad budget. The pharmacies do not really play a role in marketing - they just fill the prescriptions.

IMO the choice of ITF has extended the timeline until revenues for SPL can even be projected. But we have become accustomed to extended timelines, haven't we?